Medical Microinstruments (MMI) was founded in 2015 near Pisa, Italy, to bring robotics to microsurgery, an extraordinarily demanding discipline in which surgeons reconnect blood vessels, nerves and lymphatic channels often less than a millimeter in diameter. At that scale, the natural tremor and limited dexterity of even expert human hands become significant barriers, and many advanced reconstructive and lymphatic procedures remain restricted to a handful of elite surgeons.
The company's flagship Symani Surgical System addresses this with what MMI describes as the world's smallest wristed robotic instruments. Mounted on two robotic arms, these micro-instruments replicate the dexterity of a human hand at a vastly smaller scale, with seven degrees of freedom for natural, articulated movement. The system layers in tremor filtration and motion scaling, translating a surgeon's larger hand movements into precise, smooth micro-movements and removing the shake that would otherwise make sub-millimeter work treacherous.
Symani is designed for open soft-tissue microsurgery and supermicrosurgery, including lymphedema treatment, breast reconstruction after cancer, head and neck reconstruction, and trauma and limb repair. By making these procedures more precise and more teachable, MMI aims to expand access to advanced reconstructive surgery beyond the small group of specialists who can perform it manually today.
The Symani system has achieved important regulatory milestones, including U.S. FDA authorization as the first robotic platform for microsurgery, and is being adopted in clinical settings in Europe and the United States. In early 2025 MMI closed a $110 million Series C round to accelerate the global rollout of Symani, deepen clinical evidence and expand into new surgical indications. With a differentiated, purpose-built platform and a clear clinical need, MMI is establishing robotic microsurgery as a new category in surgical robotics.